GlaxoSmithKline to Buy Stake in Intercell AG

-
GlaxoSmithKline Plc will buy a stake in Austria’s Intercell AG in a move that analysts said underscores drugmakers’ growing interest in vaccines. Glaxo will pay 33.6 million euros ($49.5 million) as part of the alliance to develop and market Intercell’s needle-free, patch-based immunizations for traveler’s diarrhea and pandemic influenza. The London-based drugmaker also will buy as much as 5 percent of Intercell for up to 84 million euros via a staggered shareholding option, the companies said in a statement today.

XTractor Premium - A Platform for discovery, knowledge sharing, analysis and modelling of published biomedical facts.









Comments

Post a Comment

Popular posts from this blog

Top 25 Indian Bioinformatics Companies

-
Here is another, quite interesting blog page with a list of Top 25 Indian Bioinformatics Companies by a fellow blogger Nabeel Basheer, while there is no actual criteria behind listing these 25 companies. It is a good handy list just in alphabetic order for all those job seekers. More so a good chronicle of the local informatics industry as well. 1. Accelrys Software Solution Pvt Ltd. 12th Floor, Discover, ITPL, White Field, Bangalore-65. www.accelrys.com 2. Apticraft Systems (P) Ltd. 142, Electronics Complex, Pardeshipura, Indore – 452010 (M.P.), India www.apticraft.com 3. Aptuit Informatics Plot No. 100-103, Export Promotion Industrial Park, White Field, Bangalore-560066 www.aptiuit.com 4. Bigtec J. K. Towers, 8th Block, Sangam Circle,46th Cross, Bangalore-560082. www.bigtec.org 5. Bijam Biosciences Private Limited Nagarjuna Hills, Hyderabad 500 082, India www.nagarjunagroup.com 6. Bio Base Databases India Pvt Ltd. Crescent Towers, 4th Floor, No : 32/1, Crescent Road, Bnagalore -...
Read more

Abbott Laboratories Buys Piramal Healthcare Limited Biz for $3.72B

-
Abbott May 21 announced a definitive agreement with Piramal Healthcare Limited to acquire full ownership of Piramal's Healthcare Solutions business (Domestic Formulations), a leader in the Indian branded generics market, for an up-front payment of $2.12 billion , plus $400 million annually for the next four years, giving Abbott the No. 1 position in the Indian pharmaceutical market. This further accelerates Abbott's emerging markets growth following the recent acquisition of Solvay Pharmaceuticals and announcements last week of Abbott's collaboration with Zydus Cadila as well as the creation of a new stand-alone Established Products Division to focus on expanding the global markets for its leading branded generics portfolio. "This strategic action will advance Abbott into the leading market position in India , one of the world's most attractive and rapidly growing markets," said Miles D. White , chairman and chief executive officer, Abbott. ...
Read more